Science-driven development of diagnostics and therapeutics to specifically and efficiently treat prostate cancer. Diaprost is leading towards a different future.
Diaprost´s research and development is targeting prostate cancer with ambition to revolutionize personalized medicine. The goal is to establish an antibody platform, for both in vivo diagnostic, to simplify and make the identification/detection of prostate cancer more reliable, as well as for targeted therapeutics.
Diaprost was founded in 2005 based on the idea that the transformative success of the PSA assay for detection of prostate cancer could be leveraged as a personalized theranostic platform. The technology and patent applications were pursued by leading researchers at Lund University.
In the beginning of 2020 Diaprost announced that its strategic partner has exercised its option to acquire the rights to its h11B6 antibody.
Diaprost is collaborating with leading international experts in the fields of molecular medicine, biotechnology, immunology, radiology, radiation physics, laboratory medicine, and oncology. Our scientists are active at some of the world´s most prominent centers in cancer research.
Chairman of the Board